

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended December 31, 2020**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 001-15317**

**ResMed Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation or organization)

**98-0152841**

(I.R.S. Employer Identification No.)

**9001 Spectrum Center Blvd.**

**San Diego, CA 92123**

**United States of America**

(Address of principal executive offices)

**(858) 836-5000**

(Registrant's telephone number, including area code)

**Securities registered pursuant to Section 12(b) of the Exchange Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.004 per share	RMD	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer	<input checked="" type="checkbox"/>	Accelerated Filer	<input type="checkbox"/>
Non-Accelerated Filer	<input type="checkbox"/>	Smaller Reporting Company	<input type="checkbox"/>
Emerging Growth Company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At January 25, 2021, there were 145,509,084 shares of Common Stock (\$0.004 par value) outstanding. This number excludes 41,836,234 shares held by the registrant as treasury shares.

RESMED INC. AND SUBSIDIARIES

INDEX

<b>Part I</b>	<b><a href="#">Financial Information</a></b>	3
Item 1	<a href="#">Financial Statements</a>	3
	<a href="#">Condensed Consolidated Balance Sheets (Unaudited)</a>	3
	<a href="#">Condensed Consolidated Statements of Income (Unaudited)</a>	4
	<a href="#">Condensed Consolidated Statements of Comprehensive Income (Unaudited)</a>	5
	<a href="#">Condensed Consolidated Statements of Changes in Equity (Unaudited)</a>	6
	<a href="#">Condensed Consolidated Statements of Cash Flows (Unaudited)</a>	8
	<a href="#">Notes to the Condensed Consolidated Financial Statements (Unaudited)</a>	9
Item 2	<a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>	18
Item 3	<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	30
Item 4	<a href="#">Controls and Procedures</a>	32
<b>Part II</b>	<b><a href="#">Other Information</a></b>	33
Item 1	<a href="#">Legal Proceedings</a>	33
Item 1A	<a href="#">Risk Factors</a>	33
Item 2	<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	33
Item 3	<a href="#">Defaults Upon Senior Securities</a>	33
Item 4	<a href="#">Mine Safety Disclosures</a>	33
Item 5	<a href="#">Other Information</a>	33
Item 6	<a href="#">Exhibits</a>	34
	<a href="#">Signatures</a>	35

**Item 1. Financial Statements**

**RESMED INC. AND SUBSIDIARIES**  
Condensed Consolidated Balance Sheets (Unaudited)  
(In US\$ and in thousands, except share and per share data)

	December 31, 2020	June 30, 2020
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 255,865	\$ 463,156
Accounts receivable, net of allowances of \$33,593 and \$28,508 at December 31, 2020 and June 30, 2020, respectively	509,364	474,643
Inventories (note 3)	474,821	416,915
Prepaid expenses and other current assets	211,435	168,745
<b>Total current assets</b>	<b>1,451,485</b>	<b>1,523,459</b>
Non-current assets:		
Property, plant and equipment, net (note 3)	459,472	417,335
Operating lease right-of-use assets	131,291	118,348
Goodwill (note 4)	1,910,492	1,890,324
Other intangible assets, net (note 3)	412,998	448,168
Deferred income taxes	49,628	41,065
Prepaid taxes and other non-current assets	157,490	148,677
<b>Total non-current assets</b>	<b>3,121,371</b>	<b>3,063,917</b>
<b>Total assets</b>	<b>\$ 4,572,856</b>	<b>\$ 4,587,376</b>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 122,166	\$ 135,786
Accrued expenses	280,332	270,353
Operating lease liabilities, current	22,445	21,263
Deferred revenue	105,238	98,617
Income taxes payable (note 6)	35,166	64,755
Short-term debt, net (note 8)	11,988	11,987
<b>Total current liabilities</b>	<b>577,335</b>	<b>602,761</b>
Non-current liabilities:		
Deferred revenue	86,899	87,307
Deferred income taxes	12,733	13,011
Operating lease liabilities, non-current	117,641	101,880
Other long-term liabilities	9,481	8,347
Long-term debt, net (note 8)	813,732	1,164,133
Long-term income taxes payable (note 6)	90,051	112,910
<b>Total non-current liabilities</b>	<b>1,130,537</b>	<b>1,487,588</b>
<b>Total liabilities</b>	<b>1,707,872</b>	<b>2,090,349</b>
Commitments and contingencies (note 10)		
Stockholders' equity:		
Preferred stock, \$0.01 par value, 2,000,000 shares authorized; none issued	-	-
Common stock, \$0.004 par value, 350,000,000 shares authorized; 187,340,332 issued and 145,504,098 outstanding at December 31, 2020 and 186,723,407 issued and 144,887,175 outstanding at June 30, 2020	582	580
Additional paid-in capital	1,574,240	1,570,694
Retained earnings	3,076,569	2,832,991
Treasury stock, at cost, 41,836,234 shares at December 31, 2020 and June 30, 2020	(1,623,256)	(1,623,256)
Accumulated other comprehensive loss	(163,151)	(283,982)
<b>Total stockholders' equity</b>	<b>2,864,984</b>	<b>2,497,027</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 4,572,856</b>	<b>\$ 4,587,376</b>

See the accompanying notes to the unaudited condensed consolidated financial statements.

**RESMED INC. AND SUBSIDIARIES**
**Condensed Consolidated Statements of Income (Unaudited)**

(In US\$ and in thousands, except per share data)

	<b>Three Months Ended December 31,</b>		<b>Six Months Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>	<b>2020</b>	<b>2019</b>
Net revenue - Sleep and Respiratory Care products	\$ 708,178	\$ 649,451	\$ 1,367,979	\$ 1,243,617
Net revenue - Software as a Service	91,833	86,706	183,976	173,596
Net revenue	800,011	736,157	1,551,955	1,417,213
Cost of sales - Sleep and Respiratory Care products	293,862	267,377	562,852	513,793
Cost of sales - Software as a Service	32,502	29,598	64,816	59,183
Cost of sales (exclusive of amortization shown separately below)	326,364	296,975	627,668	572,976
Amortization of acquired intangible assets - Sleep and Respiratory Care products	1,140	2,205	3,095	4,456
Amortization of acquired intangible assets - Software as a Service	10,024	9,847	20,048	21,032
Amortization of acquired intangible assets	11,164	12,052	23,143	25,488
Total cost of sales	337,528	309,027	650,811	598,464
Gross profit	462,483	427,130	901,144	818,749
Selling, general and administrative	169,470	171,422	328,459	338,862
Research and development	54,935	49,943	109,468	97,976
Amortization of acquired intangible assets	7,689	8,556	15,932	13,599
Restructuring expenses (note 11)	8,673	-	8,673	-
Litigation settlement expenses	-	(600)	-	(600)
Total operating expenses	240,767	229,321	462,532	449,837
Income from operations	221,716	197,809	438,612	368,912
Other income (loss), net:				
Interest income	132	202	249	650
Interest expense	(5,924)	(10,220)	(12,766)	(21,212)
Loss attributable to equity method investments (note 5)	(2,640)	(6,924)	(4,928)	(13,786)
Other, net	(2,692)	(2,115)	5,279	(5,225)
Total other income (loss), net	(11,124)	(19,057)	(12,166)	(39,573)
Income before income taxes	210,592	178,752	426,446	329,339
Income taxes	31,078	18,198	68,560	48,637
Net income	\$ 179,514	\$ 160,554	\$ 357,886	\$ 280,702
Basic earnings per share (note 9)	\$ 1.24	\$ 1.11	\$ 2.47	\$ 1.95
Diluted earnings per share (note 9)	\$ 1.23	\$ 1.10	\$ 2.45	\$ 1.93
Dividend declared per share	\$ 0.39	\$ 0.39	\$ 0.78	\$ 0.78
Basic shares outstanding (000's)	145,246	144,212	145,053	143,966
Diluted shares outstanding (000's)	146,421	145,575	146,350	145,479

See the accompanying notes to the unaudited condensed consolidated financial statements.

**RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(In US\$ and in thousands)

	Three Months Ended December 31,		Six Months Ended December 31,	
	2020	2019	2020	2019
Net income	\$ 179,514	\$ 160,554	\$ 357,886	\$ 280,702
Other comprehensive income (loss):				
Foreign currency translation (loss) gain adjustments	77,040	44,467	120,831	6,891
Comprehensive income	<u>\$ 256,554</u>	<u>\$ 205,021</u>	<u>\$ 478,717</u>	<u>\$ 287,593</u>

See the accompanying notes to the unaudited condensed consolidated financial statements.

**RESMED INC. AND SUBSIDIARIES**
**Condensed Consolidated Statements of Changes in Equity (Unaudited)**  
(In US\$ and in thousands)

	Common Stock		Additional	Treasury Stock		Retained	Accumulated	
	Shares	Amount	Paid-in	Shares	Amount	Earnings	Other	Total
			Capital				Comprehensive	
							Income (Loss)	
<b>Balance, June 30, 2020</b>	<b>186,723</b>	<b>\$ 580</b>	<b>\$ 1,570,694</b>	<b>(41,836)</b>	<b>\$ (1,623,256)</b>	<b>\$ 2,832,991</b>	<b>\$ (283,982)</b>	<b>\$ 2,497,027</b>
Common stock issued on exercise of options	18	-	1,026	-	-	-	-	1,026
Common stock issued on vesting of restricted stock units, net of shares withheld for tax	3	-	227	-	-	-	-	227
Stock-based compensation costs	-	-	16,071	-	-	-	-	16,071
Other comprehensive income	-	-	-	-	-	-	43,791	43,791
Cumulative effect adjustment from adoption of the credit loss standard, net of tax	-	-	-	-	-	(1,143)	-	(1,143)
Net income	-	-	-	-	-	178,372	-	178,372
Dividends declared	-	-	-	-	-	(56,511)	-	(56,511)
<b>Balance, September 30, 2020</b>	<b>186,744</b>	<b>\$ 580</b>	<b>\$ 1,588,018</b>	<b>(41,836)</b>	<b>\$ (1,623,256)</b>	<b>\$ 2,953,709</b>	<b>\$ (240,191)</b>	<b>\$ 2,678,860</b>
Common stock issued on exercise of options	29	-	1,857	-	-	-	-	1,857
Common stock issued on vesting of restricted stock units, net of shares withheld for tax	451	2	(46,734)	-	-	-	-	(46,732)
Common stock issued on employee stock purchase plan	116	-	15,729	-	-	-	-	15,729
Stock-based compensation costs	-	-	15,370	-	-	-	-	15,370
Other comprehensive income	-	-	-	-	-	-	77,040	77,040
Net income	-	-	-	-	-	179,514	-	179,514
Dividends declared	-	-	-	-	-	(56,654)	-	(56,654)
<b>Balance, December 31, 2020</b>	<b>187,340</b>	<b>\$ 582</b>	<b>\$ 1,574,240</b>	<b>(41,836)</b>	<b>\$ (1,623,256)</b>	<b>\$ 3,076,569</b>	<b>\$ (163,151)</b>	<b>\$ 2,864,984</b>

See the accompanying notes to the unaudited condensed consolidated financial statements.

**RESMED INC. AND SUBSIDIARIES**
**Condensed Consolidated Statements of Changes in Equity (Unaudited)**  
(In US\$ and in thousands)

	Common Stock		Additional	Treasury Stock		Retained	Accumulated	
	Shares	Amount	Paid-in	Shares	Amount	Earnings	Other	Total
			Capital				Comprehensive	
							Income (Loss)	
<b>Balance, June 30, 2019</b>	<b>185,491</b>	<b>\$ 575</b>	<b>\$ 1,511,473</b>	<b>(41,836)</b>	<b>\$ (1,623,256)</b>	<b>\$ 2,436,410</b>	<b>\$ (253,009)</b>	<b>\$ 2,072,193</b>
Common stock issued on exercise of options	110	-	5,609	-	-	-	-	5,609
Common stock issued on vesting of restricted stock units, net of shares withheld for tax	4	-	(327)	-	-	-	-	(327)
Stock-based compensation costs	-	-	13,256	-	-	-	-	13,256
Other comprehensive income	-	-	-	-	-	-	(37,576)	(37,576)
Net income	-	-	-	-	-	120,148	-	120,148
Dividends declared	-	-	-	-	-	(56,052)	-	(56,052)
<b>Balance, September 30, 2019</b>	<b>185,605</b>	<b>\$ 575</b>	<b>\$ 1,530,011</b>	<b>(41,836)</b>	<b>\$ (1,623,256)</b>	<b>\$ 2,500,506</b>	<b>\$ (290,585)</b>	<b>\$ 2,117,251</b>
Common stock issued on exercise of options	117	-	6,498	-	-	-	-	6,498
Common stock issued on vesting of restricted stock units, net of shares withheld for tax	576	3	(40,764)	-	-	-	-	(40,761)
Common stock issued on employee stock purchase plan	137	-	12,190	-	-	-	-	12,190
Stock-based compensation costs	-	-	14,057	-	-	-	-	14,057
Other comprehensive income	-	-	-	-	-	-	44,467	44,467
Net income	-	-	-	-	-	160,554	-	160,554
Dividends declared	-	-	-	-	-	(56,150)	-	(56,150)
<b>Balance, December 31, 2019</b>	<b>186,435</b>	<b>\$ 578</b>	<b>\$ 1,521,992</b>	<b>(41,836)</b>	<b>\$ (1,623,256)</b>	<b>\$ 2,604,910</b>	<b>\$ (246,118)</b>	<b>\$ 2,258,106</b>

See the accompanying notes to the unaudited condensed consolidated financial statements.

**RESMED INC. AND SUBSIDIARIES**  
Condensed Consolidated Statements of Cash Flows (Unaudited)  
(In US\$ and in thousands)

	<b>Six Months Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>
<b>Cash flows from operating activities:</b>		
Net income	\$ 357,886	\$ 280,702
Adjustment to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	80,046	77,077
Amortization of right-of-use assets	17,911	12,323
Stock-based compensation costs	31,441	27,309
Loss attributable to equity method investments (note 5)	4,928	13,786
(Gain) loss on equity investments (note 5)	(4,776)	5,419
Restructuring expenses (note 11)	8,673	-
Changes in fair value of business combination contingent consideration	500	(7)
Changes in operating assets and liabilities:		
Accounts receivable	(19,259)	(275)
Inventories	(34,212)	(28,294)
Prepaid expenses, net deferred income taxes and other current assets	(29,875)	(66,818)
Accounts payable, accrued expenses and other	(99,348)	(88,927)
Net cash provided by operating activities	313,915	232,295
<b>Cash flows from investing activities:</b>		
Purchases of property, plant and equipment	(48,443)	(47,771)
Patent registration costs	(8,367)	(4,871)
Business acquisitions, net of cash acquired	(437)	(3,423)
Purchases of investments (note 5)	(14,446)	(21,841)
Proceeds on maturity of foreign currency contracts	19,922	1,064
Net cash used in investing activities	(51,771)	(76,842)
<b>Cash flows from financing activities:</b>		
Proceeds from issuance of common stock, net	18,614	24,297
Taxes paid related to net share settlement of equity awards	(46,507)	(41,091)
Payments of business combination contingent consideration	-	(302)
Proceeds from borrowings, net of borrowing costs	55,000	730,000
Repayment of borrowings	(406,000)	(700,012)
Dividends paid	(113,165)	(112,202)
Net cash used in financing activities	(492,058)	(99,310)
Effect of exchange rate changes on cash	22,623	824
Net increase (decrease) in cash and cash equivalents	(207,291)	56,967
Cash and cash equivalents at beginning of period	463,156	147,128
Cash and cash equivalents at end of period	\$ 255,865	\$ 204,095
<b>Supplemental disclosure of cash flow information:</b>		
Income taxes paid, net of refunds	\$ 138,247	\$ 141,948
Interest paid	\$ 12,766	\$ 21,212

See the accompanying notes to the unaudited condensed consolidated financial statements.



**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

**(1) Summary of Significant Accounting Policies**
**Organization and Basis of Presentation**

ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (“SaaS”) business in the United States that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2021.

The condensed consolidated financial statements for the three and six months ended December 31, 2020 and December 31, 2019 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2020.

**Revenue Recognition**

In accordance with Accounting Standard Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers”, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (“Sleep and Respiratory Care”) and the supply of business management software as a service to out-of-hospital health providers (“SaaS”). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.

Disaggregation of revenue

The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2020	2019	2020	2019
<b>U.S., Canada and Latin America</b>				
Devices	\$ 204,997	\$ 203,522	\$ 402,390	\$ 390,409
Masks and other	221,764	204,444	427,524	387,805
<b>Total Sleep and Respiratory Care</b>	<b>\$ 426,761</b>	<b>\$ 407,966</b>	<b>\$ 829,914</b>	<b>\$ 778,214</b>
Software as a Service	91,833	86,706	183,976	173,596
<b>Total</b>	<b>\$ 518,594</b>	<b>\$ 494,672</b>	<b>\$ 1,013,890</b>	<b>\$ 951,810</b>
<b>Combined Europe, Asia and other markets</b>				
Devices	\$ 187,992	\$ 162,311	\$ 364,018	\$ 314,236
Masks and other	93,425	79,174	174,047	151,167
<b>Total Sleep and Respiratory Care</b>	<b>\$ 281,417</b>	<b>\$ 241,485</b>	<b>\$ 538,065</b>	<b>\$ 465,403</b>
<b>Global revenue</b>				
Devices	\$ 392,989	\$ 365,833	\$ 766,408	\$ 704,645
Masks and other	315,189	283,618	601,571	538,972
<b>Total Sleep and Respiratory Care</b>	<b>\$ 708,178</b>	<b>\$ 649,451</b>	<b>\$ 1,367,979</b>	<b>\$ 1,243,617</b>
Software as a Service	91,833	86,706	183,976	173,596
<b>Total</b>	<b>\$ 800,011</b>	<b>\$ 736,157</b>	<b>\$ 1,551,955</b>	<b>\$ 1,417,213</b>

**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

Performance obligations and contract balances

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products are provided at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.

The following table summarizes our contract balances (in thousands):

	December 31, 2020	June 30, 2020	Balance sheet caption
<b>Contract assets</b>			
Accounts receivable, net	\$ 509,364	\$ 474,643	Accounts receivable, net
Unbilled revenue, current	9,453	9,452	Prepaid expenses and other current assets
Unbilled revenue, non-current	5,885	6,957	Prepaid taxes and other non-current assets
<b>Contract liabilities</b>			
Deferred revenue, current	(105,238)	(98,617)	Deferred revenue (current liabilities)
Deferred revenue, non-current	(86,899)	(87,307)	Deferred revenue (non-current liabilities)

Transaction price determination

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g., rebates, discounts, free goods) and returns offered to customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.

We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer's expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.

When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.

Accounting and practical expedient elections

We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have elected two practical expedients including the "right to invoice" practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.

**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

**Lease Revenue**

We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer.

The components of lease revenue were as follows (in thousands):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2020	2019	2020	2019
Sales-type lease revenue	\$ 1,863	\$ 3,068	\$ 3,823	\$ 5,326
Operating lease revenue	25,026	21,317	49,805	42,952
Total lease revenue	<u>\$ 26,889</u>	<u>\$ 24,385</u>	<u>\$ 53,628</u>	<u>\$ 48,278</u>

**Provision for Warranty**

We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.

**New Accounting Pronouncements****(a) Recently issued accounting standards not yet adopted**ASU No. 2020-04 “Reference Rate Reform: Facilitation of the Effects of Reference Rate Reform on Financial Reporting”

In March 2020, the FASB issued ASU No. 2020-04, “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (Topic 848), which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance is effective for us as of March 12, 2020 through December 31, 2022. We are currently evaluating the impact that this guidance, if elected, will have on our consolidated financial statements.

**(b) Recently adopted accounting pronouncements**ASU No. 2016-13 “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments”

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments” (Topic 326), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The guidance was adopted effective July 1, 2020 using the modified retrospective approach. We recognized the cumulative effect of adopting this guidance as an adjustment to the opening balance of retained earnings of \$1.1 million, net of tax, related to our allowance for credit losses for accounts receivable. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements.

ASU No. 2018-15 “Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract”

In August 2018, the FASB issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (Subtopic 350-40), which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance was adopted effective July 1, 2020 and will be applied prospectively. Under the new ASU, capitalized implementation costs are presented as other non-current assets on our consolidated balance sheets and within operating cash flows on our consolidated statements of cash flows. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements.

**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

**(2) Segment Information**

We have quantitatively and qualitatively determined that we operate in two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment.

We evaluate the performance of our segments based on net revenues and income from operations. The accounting policies of the segments are the same as those described in note 2 of our consolidated financial statements included in our Form 10-K for the year ended June 30, 2020. Segment net revenues and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, acquisition related expenses, interest income, interest expense and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.

The table below presents a reconciliation of net revenues and net operating profit by reportable segments (in thousands):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2020	2019	2020	2019
<b>Net revenue by segment</b>				
Total Sleep and Respiratory Care	\$ 708,178	\$ 649,451	\$ 1,367,979	\$ 1,243,617
Software as a Service	91,833	87,363	183,976	175,698
Deferred revenue fair value adjustment <sup>(1)</sup>	-	(657)	-	(2,102)
Total Software as a Service	91,833	86,706	183,976	173,596
Total	\$ 800,011	\$ 736,157	\$ 1,551,955	\$ 1,417,213
<b>Depreciation and amortization by segment</b>				
Sleep and Respiratory Care	\$ 13,244	\$ 14,187	\$ 26,391	\$ 28,878
Software as a Service	1,137	841	2,108	1,819
Amortization of acquired intangible assets and corporate assets	26,199	24,095	51,547	46,380
Total	\$ 40,580	\$ 39,123	\$ 80,046	\$ 77,077
<b>Net operating profit by segment <sup>(2)</sup></b>				
Sleep and Respiratory Care <sup>(2)</sup>	\$ 261,660	\$ 230,097	\$ 509,841	\$ 428,260
Software as a Service <sup>(2)</sup>	24,291	21,339	47,877	45,135
Total	\$ 285,951	\$ 251,436	\$ 557,718	\$ 473,395
<b>Reconciling items</b>				
Corporate costs	\$ 36,709	\$ 32,962	\$ 71,358	\$ 63,894
Amortization of acquired intangible assets	18,853	20,608	39,075	39,087
Restructuring expenses	8,673	-	8,673	-
Litigation settlement expenses	-	(600)	-	(600)
Deferred revenue fair value adjustment <sup>(1)</sup>	-	657	-	2,102
Interest expense (income), net	5,792	10,018	12,517	20,562
Loss attributable to equity method investments	2,640	6,924	4,928	13,786
Other, net	2,692	2,115	(5,279)	5,225
Income before income taxes	\$ 210,592	\$ 178,752	\$ 426,446	\$ 329,339

(1) The deferred revenue fair value adjustment is a purchase price accounting adjustment related to MatrixCare which was acquired on November 13, 2018.

(2) During the three and six months ended December 31, 2020, we recorded \$0.0 million and \$2.8 million of impairment for our operating lease right-of-use asset, respectively. The impairment related to leases for office space and was recorded within net operating profit. The impairment for the six months ended December 31, 2020 attributable to Sleep and Respiratory Care was \$1.6 million and \$1.2 million for SaaS.

**(3) Supplemental Balance Sheet Information**

Components of selected captions in the condensed consolidated balance sheets consisted of the following (in thousands):

	December 31, 2020	June 30, 2020
<b>Inventories</b>		
Raw materials	\$ 153,427	\$ 128,096
Work in progress	2,439	2,807
Finished goods	318,955	286,012
Total inventories	\$ 474,821	\$ 416,915

**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

<b>Property, Plant and Equipment</b>	<b>December 31, 2020</b>	<b>June 30, 2020</b>
Property, plant and equipment, at cost	\$ 1,060,896	\$ 969,166
Accumulated depreciation and amortization	(601,424)	(551,831)
Property, plant and equipment, net	<u>\$ 459,472</u>	<u>\$ 417,335</u>

<b>Other Intangible Assets</b>	<b>December 31, 2020</b>	<b>June 30, 2020</b>
Developed/core product technology	\$ 380,523	\$ 382,806
Accumulated amortization	(218,768)	(197,670)
Developed/core product technology, net	161,755	185,136
Customer relationships	269,718	279,370
Accumulated amortization	(87,377)	(80,922)
Customer relationships, net	182,341	198,448
Other intangibles	195,446	177,091
Accumulated amortization	(126,544)	(112,507)
Other intangibles, net	68,902	64,584
Total other intangibles, net	<u>\$ 412,998</u>	<u>\$ 448,168</u>

Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, which we amortize over the estimated useful life of the assets, generally between two years to fifteen years. There are no expected residual values related to these intangible assets.

#### (4) Goodwill

A reconciliation of changes in our goodwill by reportable segment is as follows (in thousands):

	<b>Six Months Ended December 31, 2020</b>		
	<b>Sleep and Respiratory Care</b>	<b>SaaS</b>	<b>Total</b>
Balance at the beginning of the period	\$ 614,448	\$ 1,275,876	\$ 1,890,324
Foreign currency translation adjustments	20,168	-	20,168
Balance at the end of the period	<u>\$ 634,616</u>	<u>\$ 1,275,876</u>	<u>\$ 1,910,492</u>

#### (5) Investments

We have equity investments in privately held companies that are unconsolidated entities. The following discusses our investments in marketable equity securities, non-marketable equity securities, gains and losses on marketable and non-marketable equity securities, as well as our equity securities accounted for under the equity method.

Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets.

Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the condensed consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We estimate the fair value of our non-marketable equity investments using Level 3 inputs to assess whether impairment losses shall be recorded. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in other, net on the condensed consolidated statements of income.

Equity investments whereby we have significant influence but not control over the investee, and are not the primary beneficiary of the investee's activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other, net on the condensed consolidated statements of income.

Equity investments by measurement category were as follows (in thousands):

<b>Measurement category</b>	<b>December 31, 2020</b>	<b>June 30, 2020</b>
Fair value	\$ 15,345	\$ -
Measurement alternative	21,410	30,033
Equity method	21,681	14,109
Total	<u>\$ 58,436</u>	<u>\$ 44,142</u>



**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

The following table shows a reconciliation of the changes in our non-marketable equity investments (in thousands):

	Six Months Ended December 31,	
	2020	2019
<b>Non-marketable securities</b>		
Balance at the beginning of the period	\$ 30,033	\$ 30,436
Investments	1,946	4,341
Impairment of investments	-	(5,419)
Reclassification to marketable securities <sup>(1)</sup>	(10,569)	-
Carrying value of non-marketable securities	<u>\$ 21,410</u>	<u>\$ 29,358</u>

(1) During the six months ended December 31, 2020, one of our investments, which was previously accounted for under the measurement alternative, completed its initial public offering which resulted in a change of accounting methodology to fair value.

Net unrealized gains and losses recognized for equity investments held as of December 31, 2020 were a loss of \$3.7 million for three months ended December 31, 2020 and a gain of \$4.8 million for six months ended December 31, 2020, which related to publicly traded marketable equity securities. Net unrealized losses recognized for equity investments held as of December 31, 2019 for the three and six months ended December 31, 2019 were \$2.8 million and \$5.4 million, respectively, which related to impairments of privately held non-marketable securities.

The following table shows a reconciliation of the changes in our equity securities accounted for under the equity method (in thousands):

	Six Months Ended December 31,	
	2020	2019
<b>Equity method investments</b>		
Balance at the beginning of the period	\$ 14,109	\$ 21,667
Investments	12,500	17,500
Loss attributable to equity method investments	(4,928)	(13,786)
Carrying value of equity method investments	<u>\$ 21,681</u>	<u>\$ 25,381</u>

## (6) Income Taxes

In accordance with ASC 740 *Income Taxes*, each interim reporting period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.

Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results.

We are under audit by the ATO in three different cycles: tax years 2009 to 2013, tax years 2014 to 2017 and tax year 2018. We received Notices of Amended Assessments from the ATO for the tax years 2009 to 2013. Based on these assessments, the ATO asserted that we owe \$151.7 million in additional income tax and \$38.4 million in accrued interest, of which \$75.9 million was paid in April 2018 under a payment arrangement with the ATO. In June 2018, we received a notice from the ATO claiming penalties of 50% of the additional income tax that was assessed, or \$75.9 million. As of December 31, 2020, we recorded a receivable in prepaid taxes and other non-current assets for the amount paid in April 2018 as we ultimately expect this will be refunded by the ATO. We do not agree with the ATO's assessments and we continue to believe we are more likely than not to be successful in defending our position. However, if we are not successful, we will not receive a refund of the amount paid in April 2018 and we would be required to pay the remaining additional income tax, accrued interest and penalties, which would be recorded as income tax expense.

**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

**(7) Product Warranties**

Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, are as follows (in thousands):

	Six Months Ended December 31,	
	2020	2019
Balance at the beginning of the period	\$ 21,132	\$ 19,625
Warranty accruals for the period	8,309	6,776
Warranty costs incurred for the period	(7,075)	(6,191)
Foreign currency translation adjustments	1,903	76
Balance at the end of the period	<u>\$ 24,269</u>	<u>\$ 20,286</u>

**(8) Debt**

Debt consisted of the following (in thousands):

	December 31, 2020	June 30, 2020
Short-term debt	\$ 12,000	\$ 12,000
Deferred borrowing costs	(12)	(13)
Short-term debt, net	<u>11,988</u>	<u>11,987</u>
Long-term debt	\$ 817,000	\$ 1,168,000
Deferred borrowing costs	(3,268)	(3,867)
Long-term debt, net	<u>\$ 813,732</u>	<u>\$ 1,164,133</u>
Total debt	<u>\$ 825,720</u>	<u>\$ 1,176,120</u>

**Credit Facility**

On April 17, 2018, we entered into an amended and restated credit agreement (the “Revolving Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, joint book runner, swing line lender and letter of credit issuer, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of \$800.0 million, with an uncommitted option to increase the revolving credit facility by an additional \$300.0 million.

Additionally, on April 17, 2018, ResMed Limited entered into a Syndicated Facility Agreement (the “Term Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Term Credit Agreement, among other things, provides ResMed Limited a senior unsecured term credit facility of \$200.0 million.

On November 5, 2018, we entered into a first amendment to the Revolving Credit Agreement to, among other things, increase the size of our senior unsecured revolving credit facility from \$800.0 million to \$1.6 billion, with an uncommitted option to increase the revolving credit facility by an additional \$300.0 million.

Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Limited’s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement.

The Revolving Credit Agreement and Term Credit Agreement each terminate on April 17, 2023, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a \$6.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to LIBOR plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At December 31, 2020, the interest rate that was being charged on the outstanding principal amounts was 1.1%. An applicable commitment

**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

fee of 0.100% to 0.175% (depending on the then-applicable leverage ratio) applies on the unused portion of the revolving credit facility. As of December 31, 2020, we had \$1.4 billion available for draw down under the revolving credit facility.

We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements' interest rate is calculated as LIBOR plus the spreads described above, its carrying amount is equivalent to its fair value as at December 31, 2020 and June 30, 2020, which was \$329.0 million and \$680.0 million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 1) were used to estimate fair value.

### Senior Notes

On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of \$250.0 million principal amount of our 3.24% senior notes due July 10, 2026, and \$250.0 million principal amount of our 3.45% senior notes due July 10, 2029 (collectively referred to as the "Senior Notes"). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree LLC, Brightree Home Health & Hospice LLC, Brightree Patient Collections LLC, ResMed Operations Inc., HEALTHCAREfirst Holding Company, HCF Holdco Company, HEALTHCAREfirst, Inc., CareFacts Information Systems, LLC and Lewis Computer Services, LLC, MatrixCare Holdings Inc., MatrixCare, Inc., Reciprocal Labs Corporation and ResMed SaaS Inc., under a Subsidiary Guaranty Agreement dated as of July 10, 2019. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.

Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter.

We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of December 31, 2020, the Senior Notes have a carrying amount of \$500.0 million, excluding deferred borrowing costs, and an estimated fair value of \$546.1 million. Quoted market prices in active markets for identical liabilities based inputs (Level 1) were used to estimate fair value.

At December 31, 2020, we were in compliance with our debt covenants and there was \$829.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.

### (9) Earnings Per Share

Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.

The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 196,856 and 73,509 for the three months ended December 31, 2020 and 2019, respectively, and 154,888 and 88,624 for the six months ended December 31, 2020 and 2019, respectively as the effect would have been anti-dilutive.

Basic and diluted earnings per share are calculated as follows (in thousands except per share data):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2020	2019	2020	2019
<b>Numerator:</b>				
Net income	\$ 179,514	\$ 160,554	\$ 357,886	\$ 280,702
<b>Denominator:</b>				
Basic weighted-average common shares outstanding	145,246	144,212	145,053	143,966
Effect of dilutive securities:				
Stock options and restricted stock units	1,175	1,363	1,297	1,513
Diluted weighted average shares	146,421	145,575	146,350	145,479
Basic earnings per share	\$ 1.24	\$ 1.11	\$ 2.47	\$ 1.95
Diluted earnings per share	\$ 1.23	\$ 1.10	\$ 2.45	\$ 1.93



**RESMED INC. AND SUBSIDIARIES**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

**(10) Legal Actions and Contingencies****Litigation**

In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.

**Taxation Matters**

As described in note 6 – Income Taxes, we are under audit by the ATO in three different cycles: tax years 2009 to 2013, tax years 2014 to 2017 and tax year 2018. We received Notices of Amended Assessments from the ATO for the tax years 2009 to 2013. Based on these assessments, the ATO asserted that we owe \$151.7 million in additional income tax and \$38.4 million in accrued interest, of which \$75.9 million was paid in April 2018 under a payment arrangement with the ATO. In June 2018, we received a notice from the ATO claiming penalties of 50% of the additional income tax that was assessed, or \$75.9 million. As of December 31, 2020, we recorded a receivable in prepaid taxes and other non-current assets for the amount paid in April 2018 as we ultimately expect this will be refunded by the ATO. We do not agree with the ATO's assessments and we continue to believe we are more likely than not to be successful in defending our position. However, if we are not successful, we will not receive a refund of the amount paid in April 2018 and we would be required to pay the remaining additional income tax, accrued interest and penalties, which would be recorded as income tax expense.

**Contingent Obligations Under Recourse Provisions**

We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions' credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer's receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.

During the six months ended December 31, 2020 and December 31, 2019, receivables sold with limited recourse were \$72.6 million and \$59.3 million, respectively. As of December 31, 2020, the maximum exposure on outstanding receivables sold with recourse and contingent provision were \$27.0 million and \$7.9 million, respectively. As of June 30, 2020, the maximum exposure on outstanding receivables sold with recourse and contingent provision were \$22.8 million and \$6.6 million, respectively.

**(11) Restructuring Expenses**

In November 2020, we closed our Portable Oxygen Concentrator business, which was part of the Sleep and Respiratory Care segment. During the three and six months ended December 31, 2020, we recognized restructuring expenses of \$13.9 million primarily related to inventory write-downs of \$5.2 million, accelerated amortization of acquired intangible assets of \$5.1 million, asset impairments of \$2.3 million, employee-related costs of \$0.7 million and contract cancellation costs of \$0.6 million. Of the total expense recognized during the three and six months ended December 31, 2020, the inventory write-down of \$5.2 million is presented within cost of sales and the remaining \$8.7 million in restructuring costs is separately disclosed as restructuring expenses on the condensed consolidated statements of income. As of December 31, 2020, an outstanding, unpaid balance of \$2.6 million had been recorded as a liability in accrued expenses. We do not expect to incur additional expenses in connection with this activity in the future.

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Special Note Regarding Forward-Looking Statements**

This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “will continue,” “will,” “estimate,” “plan,” “future” and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, litigation, and tax outlook. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements reflect the views of our management at the time the statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in our annual report on Form 10-K for the fiscal year ended June 30, 2020 and elsewhere in this report.

In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, economic, market, legal or regulatory circumstances, including the impact of public health crises such as the novel strain of coronavirus (COVID-19) that has spread globally; changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities and various other factors. If any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in our forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.

Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described in our annual report on Form 10-K for the fiscal year ended June 30, 2020, in addition to the other cautionary statements and risks described elsewhere in this report and in our other filings with the Securities and Exchange Commission (“SEC”), including our subsequent reports on Forms 10-Q and 8-K. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline and you may lose all or part of your investment.

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Overview**

The following is an overview of our results of operations for the three and six months ended December 31, 2020. Management's discussion and analysis of financial condition and results of operations ("MD&A") is intended to help the reader understand our results of operations and financial condition. Management's discussion and analysis is provided as a supplement to, and should be read in conjunction with, the condensed consolidated financial statements and notes included in this report.

We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing ("SDB"), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Our products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. Our cloud-based software digital health applications, along with our devices, are designed to provide connected care to improve patient outcomes and efficiencies for our customers.

Since the development of continuous positive airway pressure therapy, we have expanded our business by developing or acquiring a number of products and solutions for a broader range of respiratory disorders including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators and cloud-based software informatics solutions to manage patient outcomes and customer and provider business processes. Our growth has been fueled by geographic expansion, our research and product development efforts, acquisitions and an increasing awareness of SDB and respiratory conditions like chronic obstructive pulmonary disease as significant health concerns.

We are committed to ongoing investment in research and development and product enhancements. During the three months ended December 31, 2020, we invested \$54.9 million on research and development activities, which represents 6.9% of net revenues, with a continued focus on the development and commercialization of new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers and help physicians and providers better manage chronic disease and lower healthcare costs. Due to multiple acquisitions, including Brightree in April 2016, HEALTHCAREfirst in July 2018 and MatrixCare in November 2018, our operations now include out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. These platforms comprise our SaaS business. These products, our cloud-based remote monitoring and therapy management system, and a robust product pipeline, should continue to provide us with a strong platform for future growth.

We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care") and the supply of business management software as a service to out-of-hospital health providers ("SaaS").

During the three months ended December 31, 2020, our net revenue increased by 9% compared to the three months ended December 31, 2019. Gross margin was 57.8% for the three months ended December 31, 2020 compared to 58.0% for the three months ended December 31, 2019. Diluted earnings per share for the three months ended December 31, 2020 was \$1.23 per share, compared to \$1.10 per share for the three months ended December 31, 2019.

At December 31, 2020, our cash and cash equivalents totaled \$255.9 million, our total assets were \$4.6 billion and our stockholders' equity was \$2.9 billion.

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a "constant currency" basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with accounting principles generally accepted in the United States ("GAAP").

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Impact of COVID-19**

In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus ("COVID-19") as a pandemic. Our primary goal during the COVID-19 pandemic is the preservation of life. We have prioritized protecting the health and safety of our employees and continuing to use our employees' talents and our resources to help society meet and overcome the challenges the pandemic poses.

During the three months ended December 31, 2020, we observed minimal incremental demand for our ventilator devices and masks associated with the COVID-19 pandemic. Although there is still substantial uncertainty, we believe the global demand for ventilators and other respiratory support devices, used to treat COVID-19 patients, has largely been met. As such, we expect minimal COVID-19 generated demand for our ventilator products for the second half of the fiscal year ending June 30, 2021.

Diagnostic pathways for sleep apnea treatment, including HME suppliers and sleep clinics, have been impacted and, in some instances, been required, or in the future may be required, to temporarily close due to governments' "shelter-in-place" orders, quarantines or similar orders or restrictions enacted to control the spread of COVID-19. In some countries, new patients are prescribed sleep apnea treatment through hospitals that are directing their resources to critical care, including COVID-19 treatment. The impact on these diagnostic and prescription pathways has resulted in a decrease in demand from new patients for our products designed to treat sleep apnea. Given the ongoing uncertainty regarding the duration and extent of the COVID-19 pandemic and measures taken to control the spread of COVID-19, we are uncertain as to the duration and extent of the impact on demand for our sleep devices. However, due to the nature of the installed base of existing patients using our devices, we have not seen any significant adverse impact on demand for re-supply of our masks.

Our SaaS business has also been affected by COVID-19 and measures taken to control the spread of COVID-19. Some of our existing and potential SaaS customers are HME distributors and, therefore, have been impacted, or may be impacted, by the same temporary business closures noted above. We also have existing and potential SaaS customers that operate care facilities and are either receiving and treating patients infected with COVID-19 or are implementing significant measures to safeguard their facilities against a potential COVID-19 outbreak. Given these challenging business conditions and the uncertain economic environment, we believe businesses have been less willing to adopt new or change SaaS platforms, which has adversely impacted our ability to engage new customers for our SaaS businesses, or expand the services used by existing customers.

Our ability to continue to operate without any significant negative impacts will in part depend on our ability to protect our employees. We have endeavored and continue to follow recommended actions of government and health authorities to protect our employees worldwide, but since COVID-19 was declared a pandemic in March 2020, we were able to broadly maintain our operations, and we are beginning the slow and careful process of progressively returning to work in some of our offices around the world. The pandemic has not negatively impacted our liquidity position.

**RESMED INC. AND SUBSIDIARIES**
**Management's Discussion and Analysis of Financial Condition and Results of Operations**
**Three Months Ended December 31, 2020 Compared to the Three Months Ended December 31, 2019**
**Net Revenue**

Net revenue for the three months ended December 31, 2020 increased to \$800.0 million from \$736.2 million for the three months ended December 31, 2019, an increase of \$63.9 million or 9% (a 7% increase on a constant currency basis). The following table summarizes our net revenue disaggregated by segment, product and region for the three months ended December 31, 2020 compared to December 31, 2019 (in thousands):

	Three Months Ended December 31,		% Change	Constant Currency*
	2020	2019		
<b>U.S., Canada and Latin America</b>				
Devices	\$ 204,997	\$ 203,522	1 %	
Masks and other	221,764	204,444	8	
Total Sleep and Respiratory Care	\$ 426,761	\$ 407,966	5	
Software as a Service	91,833	86,706	6	
Total	\$ 518,594	\$ 494,672	5	
<b>Combined Europe, Asia and other markets</b>				
Devices	\$ 187,992	\$ 162,311	16 %	10 %
Masks and other	93,425	79,174	18	12
Total Sleep and Respiratory Care	\$ 281,417	\$ 241,485	17	10
<b>Global revenue</b>				
Devices	\$ 392,989	\$ 365,833	7 %	5 %
Masks and other	315,189	283,618	11	9
Total Sleep and Respiratory Care	\$ 708,178	\$ 649,451	9	7
Software as a Service	91,833	86,706	6	6
Total	\$ 800,011	\$ 736,157	9	7

\* Constant currency numbers exclude the impact of movements in international currencies.

**Sleep and Respiratory Care**

Net revenue from our Sleep and Respiratory Care business for the three months ended December 31, 2020 was \$708.2 million, an increase of 9% compared to net revenue for the three months ended December 31, 2019. Movements in international currencies against the U.S. dollar positively impacted net revenue by approximately \$14.9 million for the three months ended December 31, 2020. Excluding the impact of currency movements, total Sleep and Respiratory Care net revenue for the three months ended December 31, 2020 increased 7% compared to the three months ended December 31, 2019. The increase in net revenue was primarily attributable to an increase in unit sales of our devices and masks.

Net revenue from our Sleep and Respiratory Care business in the U.S., Canada and Latin America for the three months ended December 31, 2020 increased to \$426.8 million from \$408.0 million for the three months ended December 31, 2019, an increase of \$18.8 million or 5%. The increase was primarily due to an increase in unit sales of our masks.

Net revenue in combined Europe, Asia and other markets increased for the three months ended December 31, 2020 to \$281.4 million from \$241.5 million for the three months ended December 31, 2019, an increase of \$39.9 million or 17% (a 10% increase on a constant currency basis). The constant currency increase in sales in combined Europe, Asia and other markets predominantly reflects an increase in unit sales of our devices and masks.

Net revenue from devices for the three months ended December 31, 2020 increased to \$393.0 million from \$365.8 million for the three months ended December 31, 2019, an increase of \$27.2 million or 7%, including an increase of 1% in the U.S., Canada and Latin America and an increase of 16% in combined Europe, Asia and other markets (a 10% increase on a constant currency basis). Excluding the impact of foreign currency movements, device sales for the three months ended December 31, 2020 increased by 5%.

Net revenue from masks and other for the three months ended December 31, 2020 increased to \$315.2 million from \$283.7 million for the three months ended December 31, 2019, an increase of \$31.5 million or 11%, including an increase of 8% in the U.S., Canada and Latin America and an increase of 18% in combined Europe, Asia and other markets (a 12% increase on a constant currency basis). Excluding the impact of foreign currency movements, masks and other sales increased by 9%, compared to the three months ended December 31, 2019.

**Software as a Service**

Net revenue from our SaaS business for the three months ended December 31, 2020 was \$91.8 million, an increase of 6% compared to the three months ended December 31, 2019. The increase was predominantly due to continued growth in resupply service offerings.

**RESMED INC. AND SUBSIDIARIES**
**Management's Discussion and Analysis of Financial Condition and Results of Operations**
**Six Months Ended December 31, 2020 Compared to the Six Months Ended December 31, 2019**
**Net Revenue**

Net revenue for the six months ended December 31, 2020 increased to \$1,552.0 million from \$1,417.2 million for the six months ended December 31, 2019, an increase of \$134.8 million or 10% (an 8% increase on a constant currency basis). The following table summarizes our net revenue disaggregated by segment, product and region for the six months ended December 31, 2020 compared to December 31, 2019 (in thousands):

	Six Months Ended December 31,		% Change	Constant Currency*
	2020	2019		
<b>U.S., Canada and Latin America</b>				
Devices	\$ 402,390	\$ 390,409	3 %	
Masks and other	427,524	387,805	10	
Total Sleep and Respiratory Care	\$ 829,914	\$ 778,214	7	
Software as a Service	183,976	173,596	6	
Total	\$ 1,013,890	\$ 951,810	7	
<b>Combined Europe, Asia and other markets</b>				
Devices	\$ 364,018	\$ 314,236	16 %	11 %
Masks and other	174,047	151,167	15	10
Total Sleep and Respiratory Care	\$ 538,065	\$ 465,403	16	10
<b>Global revenue</b>				
Devices	\$ 766,408	\$ 704,645	9 %	6 %
Masks and other	601,571	538,972	12	10
Total Sleep and Respiratory Care	\$ 1,367,979	\$ 1,243,617	10	8
Software as a Service	183,976	173,596	6	6
Total	\$ 1,551,955	\$ 1,417,213	10	8

\* Constant currency numbers exclude the impact of movements in international currencies.

**Sleep and Respiratory Care**

Net revenue from our Sleep and Respiratory Care business for the six months ended December 31, 2020 was \$1,368.0 million, an increase of 10% compared to net revenue for the six months ended December 31, 2019. Movements in international currencies against the U.S. dollar positively impacted net revenues by approximately \$24.3 million for the six months ended December 31, 2020. Excluding the impact of currency movements, total Sleep and Respiratory Care net revenue for the six months ended December 31, 2020 increased by 8% compared to the six months ended December 31, 2019. The increase in net revenue was primarily attributable to an increase in unit sales of our devices and masks.

Net revenue from our Sleep and Respiratory Care business in the U.S., Canada and Latin America for the six months ended December 31, 2020 increased to \$829.9 million from \$778.2 million for the six months ended December 31, 2019, an increase of \$51.7 million or 7%. The increase was primarily due to an increase in unit sales of our masks.

Net revenue in combined Europe, Asia and other markets increased for the six months ended December 31, 2020 to \$538.1 million from \$465.4 million for the six months ended December 31, 2019, an increase of \$72.7 million or 16% (a 10% increase on a constant currency basis). The constant currency increase in sales in combined Europe, Asia and other markets predominantly reflects an increase in unit sales of our devices and masks.

Net revenue from devices for the six months ended December 31, 2020 increased to \$766.4 million from \$704.6 million for the six months ended December 31, 2019, an increase of \$61.8 million or 9%, including an increase of 3% in the U.S., Canada and Latin America and an increase of 16% in combined Europe, Asia and other markets (a 11% increase on a constant currency basis). Excluding the impact of foreign currency movements, device sales for the six months ended December 31, 2020 increased by 6%.

Net revenue from masks and other for the six months ended December 31, 2020 increased to \$601.6 million from \$539.0 million for the six months ended December 31, 2019, an increase of \$62.6 million or 12%, including an increase of 10% in the U.S., Canada and Latin America and an increase of 15% in combined Europe, Asia and other markets (an 10% increase on a constant currency basis). Excluding the impact of foreign currency movements, masks and other sales increased by 10%, compared to the six months ended December 31, 2019.

**Software as a Service**

Net revenue from our SaaS business for the six months ended December 31, 2020 was \$184.0 million, an increase of 6% compared to the six months ended December 31, 2019. The increase was predominantly due to continued growth in resupply service offerings.



**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Gross Profit and Gross Margin**

Gross profit increased for the three months ended December 31, 2020 to \$462.5 million from \$427.1 million for the three months ended December 31, 2019, an increase of \$35.4 million or 8%. Gross margin, which is gross profit as a percentage of net revenue, for the three months ended December 31, 2020 was 57.8% compared to 58.0% for the three months ended December 31, 2019.

The decrease in gross margin for the three months ended December 31, 2020 compared to three months ended December 31, 2019 was due primarily to restructuring expense of \$5.2 million associated with inventory write-downs following the closure of the Portable Oxygen Concentrator ("POC") business, partially offset by favorable product mix, foreign currency movement and lower amortization of acquired intangibles.

Gross profit increased for the six months ended December 31, 2020 to \$901.1 million from \$818.7 million for the six months ended December 31, 2019, an increase of \$82.4 million or 10%. Gross margin for the six months ended December 31, 2020 was 58.1% compared to 57.8% for the six months ended December 31, 2019.

The increase in gross margin for the six months ended December 31, 2020 compared to the six months ended December 31, 2019 was due primarily to favorable product mix, foreign currency movements and lower amortization of acquired intangibles, partially offset by restructuring expense of \$5.2 million associated with inventory write-downs following the closure of the POC business.

**Selling, General and Administrative Expenses**

Selling, general and administrative expenses decreased for the three months ended December 31, 2020 to \$169.5 million from \$171.4 million for the three months ended December 31, 2019, a decrease of \$2.0 million or 1%. Selling, general and administrative expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately \$3.9 million, as reported in U.S. dollars. Excluding the impact of foreign currency movements, selling, general and administrative expenses for the three months ended December 31, 2020 decreased by 3% compared to the three months ended December 31, 2019. As a percentage of net revenue, selling, general and administrative expenses were 21.2% for the three months ended December 31, 2020, compared to 23.3% for the three months ended December 31, 2019.

The constant currency decrease in selling, general and administrative expenses was primarily due to decreases in travel, marketing and bad debt expenses during the three months ended December 31, 2020.

Selling, general and administrative expenses decreased for the six months ended December 31, 2020 to \$328.5 million from \$338.9 million for the six months ended December 31, 2019, a decrease of \$10.4 million or 3%. Selling, general and administrative expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately \$6.6 million, as reported in U.S. dollars. Excluding the impact of foreign currency movements, selling, general and administrative expenses for the six months ended December 31, 2020 decreased by 5% compared to the six months ended December 31, 2019. As a percentage of net revenue, selling, general and administrative expenses were 21.2% for the six months ended December 31, 2020, compared to 23.9% for the six months ended December 31, 2019.

The constant currency decrease in selling, general and administrative expenses was primarily due to decreases in travel, marketing and bad debt expenses, partially offset by a \$2.8 million impairment charge related to our right-of-use asset during the six months ended December 31, 2020.

**Research and Development Expenses**

Research and development expenses increased for the three months ended December 31, 2020 to \$54.9 million from \$49.9 million for the three months ended December 31, 2019, an increase of \$5.0 million, or 10%. Research and development expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately \$1.4 million for the three months ended December 31, 2020, as reported in U.S. dollars. Excluding the impact of foreign currency movements, research and development expenses increased by 7% compared to the three months ended December 31, 2019. As a percentage of net revenue, research and development expenses were 6.9% for the three months ended December 31, 2020, compared to 6.8% for the three months ended December 31, 2019.

The increase in research and development expenses in constant currency terms was primarily due to increases in the number of research and development personnel to facilitate development of new products and solutions.

Research and development expenses increased for the six months ended December 31, 2020 to \$109.5 million from \$98.0 million for the six months ended December 31, 2019, an increase of \$11.5 million, or 12%. Research and development expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately \$2.2 million for the six months ended December 31, 2020, as reported in U.S. dollars. Excluding the impact of foreign currency movements, research and development expenses increased by 9% compared to the six months ended December 31, 2019. As a percentage of net revenue, research

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations**

and development expenses were 7.1% for the six months ended December 31, 2020, compared to 6.9% for the six months ended December 31, 2019.

The increase in research and development expenses in constant currency terms was primarily due to increases in the number of research and development personnel to facilitate development of new products and solutions.

**Amortization of Acquired Intangible Assets**

Amortization of acquired intangible assets for the three months ended December 31, 2020 totaled \$7.7 million compared to \$8.6 million for the three months ended December 31, 2019. Amortization of acquired intangible assets for the six months ended December 31, 2020 totaled \$15.9 million compared to \$13.6 million for the six months ended December 31, 2019. The decrease in amortization of acquired intangible assets is due to historical assets becoming fully amortized.

**Restructuring Expenses**

In November 2020, we closed our POC business, which was part of the Sleep and Respiratory Care segment. During the three and six months ended December 31, 2020, we recognized restructuring expenses of \$13.9 million primarily related to inventory write-downs of \$5.2 million, accelerated amortization of acquired intangible assets of \$5.1 million, asset impairments of \$2.3 million, employee-related costs of \$0.7 million and contract cancellation costs of \$0.6 million. Of the total expense recognized during the three and six months ended December 31, 2020, the inventory write-down of \$5.2 million is presented within cost of sales and the remaining \$8.7 million in restructuring costs is separately disclosed as restructuring expenses on the condensed consolidated statements of income. We do not expect to incur additional expenses in connection with this activity in the future.

**Total Other Income (Loss), Net**

Total other income (loss), net for the three months ended December 31, 2020 was a loss of \$11.1 million compared to a loss of \$19.1 million for the three months ended December 31, 2019. The decrease was partially due to a decrease in interest expense to \$5.9 million for the three months ended December 31, 2020 compared to \$10.2 million for the three months ended December 31, 2019. We also recorded losses attributable to equity method investments for the three months ended December 31, 2020 of \$2.6 million compared to \$6.9 million for the three months ended December 31, 2019. The losses attributable to equity method investments relate to our joint venture with Verily, which is accounted for using the equity method, whereby we recognize our share of the joint venture's losses.

Total other income (loss), net for the six months ended December 31, 2020 was a loss of \$12.2 million compared to a loss of \$39.6 million for the six months ended December 31, 2019. The decrease was partially due to a decrease in interest expense to \$12.8 million for the six months ended December 31, 2020 compared to \$21.2 million for the six months ended December 31, 2019. Additionally, we recognized an unrealized gain of \$4.8 million on our marketable securities for the six months ended December 31, 2020, whereas during the six months ended December 31, 2019, we recorded an impairment of \$5.4 million on our non-marketable equity securities. We also recorded lower losses attributable to equity method investments for the six months ended December 31, 2020 of \$4.9 million compared to \$13.8 million for the six months ended December 31, 2019. The losses attributable to equity method investments relate to our joint venture with Verily, which is accounted for using the equity method, whereby we recognize our share of the joint venture's losses.

**Income Taxes**

Our effective income tax rate for the three and six months ended December 31, 2020 was 14.8% and 16.1%, respectively, as compared to 10.2% and 14.8% for the three and six months ended December 31, 2019. Our effective tax rate was impacted by windfall tax benefits related to the vesting or settlement of employee share-based awards, which reduced our income tax expenses by \$10.9 million and \$11.5 million, for the three and six months ended December 31, 2020, respectively, as compared to \$20.3 million and \$22.1 million for the three and six months ended December 31, 2019, respectively. Our Singapore operations operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. As a result of the U.S. Tax Act, we treated all non-U.S. historical earnings as taxable during the year ended June 30, 2018. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax, if repatriated.



**RESMED INC. AND SUBSIDIARIES**
**Management’s Discussion and Analysis of Financial Condition and Results of Operations**

Finally, we are under audit by the Australian Tax Office (the “ATO”) in three different cycles: tax years 2009 to 2013, tax years 2014 to 2017 and tax year 2018. We received Notices of Amended Assessments from the ATO for the tax years 2009 to 2013. Based on these assessments, the ATO asserted that we owe \$151.7 million in additional income tax and \$38.4 million in accrued interest, of which \$75.9 million was paid in April 2018 under a payment arrangement with the ATO. In June 2018, we received a notice from the ATO claiming penalties of 50% of the additional income tax that was assessed, or \$75.9 million. As of December 31, 2020, we recorded a receivable in prepaid taxes and other non-current assets for the amount paid in April 2018 as we ultimately expect this will be refunded by the ATO. We do not agree with the ATO’s assessments and we continue to believe we are more likely than not to be successful in defending our position. However, if we are not successful, we will not receive a refund of the amount paid in April 2018 and we would be required to pay the remaining additional income tax, accrued interest and penalties, which would be recorded as income tax expense.

**Net Income and Earnings per Share**

As a result of the factors above, our net income for the three months ended December 31, 2020 was \$179.5 million compared to net income of \$160.6 million for the three months ended December 31, 2019, an increase of 12% over the three months ended December 31, 2019. Our net income for the six months ended December 31, 2020 was \$357.9 million compared to net income of \$280.7 million for the six months ended December 31, 2019, an increase of 27% over the six months ended December 31, 2019.

Our diluted earnings per share for the three months ended December 31, 2020 were \$1.23 per diluted share compared to \$1.10 for the three months ended December 31, 2019, an increase of 12%. Our diluted earnings per share for the six months ended December 31, 2020 were \$2.45 per diluted share compared to \$1.93 for the six months ended December 31, 2019, an increase of 27%.

**Summary of Non-GAAP Financial Measures**

In addition to financial information prepared in accordance with GAAP, our management uses certain non-GAAP financial measures, such as non-GAAP revenue, non-GAAP cost of sales, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies.

The measure “non-GAAP revenue” is equal to GAAP net revenue once adjusted for deferred revenue fair value adjustments applied in the purchase accounting for previous business combinations. The measure “non-GAAP cost of sales” is equal to GAAP cost of sales less amortization of acquired intangible assets relating to cost of sales and restructuring expense associated with inventory write-downs following the closure of the POC business. The measure “non-GAAP gross profit” is the difference between non-GAAP revenue and non-GAAP cost of sales, and “non-GAAP gross margin” is the ratio of non-GAAP gross profit to non-GAAP revenue. These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except percentages):

	Three Months Ended		Six Months Ended	
	December 31, 2020	December 31, 2019	December 31, 2020	December 31, 2019
GAAP Net revenue	\$ 800,011	\$ 736,157	\$ 1,551,955	\$ 1,417,213
Add back: Deferred revenue fair value adjustment	-	657	-	2,102
Non-GAAP revenue	\$ 800,011	\$ 736,814	\$ 1,551,955	\$ 1,419,315
GAAP Cost of sales	\$ 337,528	\$ 309,027	\$ 650,811	\$ 598,464
Less: Amortization of acquired intangibles	(11,164)	(12,052)	(23,143)	(25,488)
Less: Restructuring - cost of sales	(5,232)	-	(5,232)	-
Non-GAAP cost of sales	\$ 321,132	\$ 296,975	\$ 622,436	\$ 572,976
GAAP gross profit	\$ 462,483	\$ 427,130	\$ 901,144	\$ 818,749
GAAP gross margin	57.8 %	58.0 %	58.1 %	57.8 %
Non-GAAP gross profit	\$ 478,879	\$ 439,839	\$ 929,519	\$ 846,339
Non-GAAP gross margin	59.9 %	59.7 %	59.9 %	59.6 %

**RESMED INC. AND SUBSIDIARIES**
**Management's Discussion and Analysis of Financial Condition and Results of Operations**

The measure “non-GAAP income from operations” is equal to GAAP income from operations once adjusted for amortization of acquired intangibles, restructuring expense associated with the closure of the POC business, deferred revenue fair value adjustments applied in the purchase accounting for previous business combinations and litigation settlement expenses. Non-GAAP income from operations reconciled with GAAP income from operations below (in thousands):

	Three Months Ended		Six Months Ended	
	December 31, 2020	December 31, 2019	December 31, 2020	December 31, 2019
GAAP income from operations	\$ 221,716	\$ 197,809	\$ 438,612	\$ 368,912
Amortization of acquired intangibles - cost of sales	11,164	12,052	23,143	25,488
Amortization of acquired intangibles - operating expenses	7,689	8,556	15,932	13,599
Restructuring - cost of sales	5,232	-	5,232	-
Restructuring - operating expenses	8,673	-	8,673	-
Deferred revenue fair value adjustment	-	657	-	2,102
Litigation settlement expenses	-	(600)	-	(600)
Non-GAAP income from operations	\$ 254,474	\$ 218,474	\$ 491,592	\$ 409,501

The measure “non-GAAP net income” is equal to GAAP net income once adjusted for amortization of acquired intangibles (net of tax), restructuring expense associated with the closure of the POC (net of tax), deferred revenue fair value adjustments applied in the purchase accounting for previous business combinations (net of tax), restructuring expenses (net of tax), litigation settlement expenses (net of tax) and fair value adjustments recognized on publicly traded marketable equity securities. The measure “non-GAAP diluted earnings per share” is the ratio of non-GAAP net income to diluted shares outstanding. These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except for per share amounts):

	Three Months Ended		Six Months Ended	
	December 31, 2020	December 31, 2019	December 31, 2020	December 31, 2019
GAAP net income	\$ 179,514	\$ 160,554	\$ 357,886	\$ 280,702
Amortization of acquired intangibles - cost of sales, net of tax	8,566	9,210	17,742	19,478
Amortization of acquired intangibles - operating expenses, net of tax	5,900	6,538	12,214	10,392
Restructuring - cost of sales, net of tax	4,663	-	4,663	-
Restructuring - operating expenses, net of tax	7,730	-	7,730	-
Deferred revenue fair value adjustment, net of tax	-	503	-	1,610
Litigation settlement expenses, net of tax	-	(528)	-	(528)
Fair value adjustment of investment	-	-	(8,476)	-
Non-GAAP net income	\$ 206,373	\$ 176,277	\$ 391,759	\$ 311,654
Diluted shares outstanding	146,421	145,575	146,350	145,479
GAAP diluted earnings per share	\$ 1.23	\$ 1.10	\$ 2.45	\$ 1.93
Non-GAAP diluted earnings per share	\$ 1.41	\$ 1.21	\$ 2.68	\$ 2.14

**Liquidity and Capital Resources**

As of December 31, 2020 and June 30, 2020, we had cash and cash equivalents of \$255.9 million and \$463.2 million, respectively. In response to the uncertainty associated with the COVID-19 pandemic, we had previously increased our cash and cash equivalents position by drawing down from our Revolving Credit Agreement. As we have not observed a significant impact to our cash flows due the pandemic, we have reduced our cash and cash equivalents and accordingly repaid our Revolving Credit Agreement. Working capital was \$874.2 million and \$920.7 million at December 31, 2020 and June 30, 2020, respectively. As of December 31, 2020, we had \$0.8 billion of borrowings compared to \$1.2 billion of borrowings at June 30, 2020. As of December 31, 2020, we had \$1.4 billion available for draw down under the revolver credit facility and a combined total of \$1.7 billion in cash and available liquidity under the revolving credit facility. We believe that cash generated from operations and available borrowings under our credit facility will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond.

As of December 31, 2020 and June 30, 2020, our cash and cash equivalent balances held within the United States amounted to \$54.2 million and \$158.8 million, respectively. Our remaining cash and cash equivalent balances at December 31, 2020 and June 30, 2020, were \$201.7 million and \$304.4 million, respectively. Our cash and cash equivalent balances are held at highly rated financial institutions.

During the year ended June 30, 2018, as a result of the U.S. Tax Act, we treated all non-U.S. historical earnings as taxable, which resulted in additional tax expense of \$126.9 million which was payable over the proceeding eight years. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated.

Inventories at December 31, 2020 were \$474.8 million, an increase of \$57.9 million or 14% from the June 30, 2020 balance of \$416.9 million. The increase in inventories was required to support our revenue growth and respond to additional complexity and elongation of our supply chain resulting from ongoing COVID-19 impacts.

## RESMED INC. AND SUBSIDIARIES

### Management’s Discussion and Analysis of Financial Condition and Results of Operations

Accounts receivable at December 31, 2020 were \$509.4 million, an increase of \$34.8 million or 7% compared to the June 30, 2020, balance of \$474.6 million. Accounts receivable days outstanding of 56 days at December 31, 2020, were lower than days outstanding of 65 days at June 30, 2020. Our allowance for doubtful accounts as a percentage of total accounts receivable at December 31, 2020, was 6.2%, compared to 5.7% at June 30, 2020.

As of December 31, 2020, we have recognized a right-of-use asset (“ROU”) of \$131.3 million and a lease liability of \$140.1 million on the balance sheet for all operating leases, other than those that meet the definition of a short-term lease.

During the six months ended December 31, 2020, we generated cash of \$313.9 million from operations compared to \$232.3 million for the six months ended December 31, 2019. The increase in cash generated from operations during the six months ended December 31, 2020, as compared to the six months ended December 31, 2019 was primarily due to the increase in operating profit, partially offset by the increase in working capital driven by higher inventory levels. Movements in foreign currency exchange rates during the six months ended December 31, 2020, had the effect of increasing our cash and cash equivalents by \$22.6 million, as reported in U.S. dollars.

We have temporarily suspended our share repurchase program due to acquisitions, and more recently, as a response to the COVID-19 pandemic. Accordingly, we did not repurchase any shares during the three and six months ended December 31, 2020 and 2019. In addition, during the six months ended December 31, 2020 and 2019, we paid dividends to holders of our common stock totaling \$113.2 million and \$112.2 million, respectively.

Capital expenditures for the six months ended December 31, 2020 and 2019, amounted to \$48.4 million and \$47.8 million, respectively. The capital expenditures for the six months ended December 31, 2020, primarily reflected investment in production tooling, leasehold improvements, equipment and machinery, and computer hardware and software. At December 31, 2020, our balance sheet reflects net property, plant and equipment of \$459.5 million compared to \$417.3 million at June 30, 2020.

### Contractual Obligations

Details of contractual obligations at December 31, 2020, are as follows (in thousands):

	Total	Payments Due by December 31,					
		2021	2022	2023	2024	2025	Thereafter
Debt	\$ 829,000	\$ 12,000	\$ 12,000	\$ 305,000	\$ -	\$ -	\$ 500,000
Interest on debt	130,701	21,630	21,630	18,360	16,725	16,725	35,631
Operating leases	133,368	26,961	21,541	17,017	13,726	11,142	42,981
Purchase obligations	400,031	397,760	1,875	396	-	-	-
Total	\$ 1,493,100	\$ 458,351	\$ 57,046	\$ 340,773	\$ 30,451	\$ 27,867	\$ 578,612

Details of other commercial commitments at December 31, 2020, are as follows (in thousands):

	Total	Amount of Commitment Expiration Per Period					
		2021	2022	2023	2024	2025	Thereafter
Standby letter of credit	\$ 17,594	\$ 3,900	\$ 8	\$ 539	\$ -	\$ -	\$ 13,147
Guarantees*	3,020	197	68	66	75	36	2,578
Total	\$ 20,614	\$ 4,097	\$ 76	\$ 605	\$ 75	\$ 36	\$ 15,725

\* The above guarantees mainly relate to requirements under contractual obligations with insurance companies transacting with our German subsidiaries and guarantees provided under our facility leasing obligations.

### Credit Facility

On April 17, 2018, we entered into an amended and restated credit agreement (as amended from time to time, the “Revolving Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, joint book runner, swing line lender and letter of credit issuer, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of \$800.0 million, with an uncommitted option to increase the revolving credit facility by an additional \$300.0 million.

Additionally, on April 17, 2018, ResMed Limited entered into a Syndicated Facility Agreement (the “Term Credit Agreement”), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Term Credit Agreement, among other things, provides ResMed Limited a senior unsecured term credit facility of \$200.0 million.

On November 5, 2018, we entered into a first amendment to the Revolving Credit Agreement to, among other things, increase the size of our senior unsecured revolving credit facility from \$800.0 million to \$1.6 billion, with an uncommitted option to increase the revolving credit facility by an additional \$300.0 million.

Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Limited’s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations**

Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement.

The Revolving Credit Agreement and Term Credit Agreement each terminate on April 17, 2023, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a \$6.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to LIBOR plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). On December 31, 2020, the interest rate that was being charged on the outstanding principal amounts was 1.1%. An applicable commitment fee of 0.100% to 0.175% (depending on the then-applicable leverage ratio) applies on the unused portion of the revolving credit facility. As of December 31, 2020, we had \$1.4 billion available for draw down under the revolving credit facility.

**Senior Notes**

On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of \$250.0 million principal amount of our 3.24% senior notes due July 10, 2026, and \$250.0 million principal amount of our 3.45% senior notes due July 10, 2029 ("Senior Notes"). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree LLC, Brightree Home Health & Hospice LLC, Brightree Patient Collections LLC, ResMed Operations Inc., HEALTHCAREfirst Holding Company, HCF Holdco Company, HEALTHCAREfirst, Inc., CareFacts Information Systems, LLC and Lewis Computer Services, LLC, MatrixCare Holdings Inc., MatrixCare, Inc., Reciprocal Labs Corporation and ResMed SaaS Inc., under a Subsidiary Guaranty Agreement dated as of July 10, 2019. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.

Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter.

On December 31, 2020, we were in compliance with our debt covenants and there was a total of \$829.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes. We expect to satisfy all of our liquidity and long-term debt requirements through a combination of cash on hand, cash generated from operations and debt facilities.

**Common Stock**

Since the inception of our share repurchase programs and through December 31, 2020, we have repurchased a total of 41.8 million shares for an aggregate of \$1.6 billion. We have temporarily suspended our share repurchase program due to recent acquisitions, and more recently, as a response to the COVID-19 pandemic. Accordingly, we did not repurchase any shares during the three and six months ended December 31, 2020 and 2019. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. At December 31, 2020, 12.9 million additional shares can be repurchased under the approved share repurchase program.

**Critical Accounting Principles and Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.

We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

For a full discussion of our critical accounting policies, see our Annual Report on Form 10-K for the year ended June 30, 2020.

**Recently Issued Accounting Pronouncements**

See note 1 to the unaudited condensed consolidated financial statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.

**Off-Balance Sheet Arrangements**

As of December 31, 2020, we are not involved in any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.

## RESMED INC. AND SUBSIDIARIES

### Quantitative and Qualitative Disclosures About Market Risk

#### Foreign Currency Market Risk

Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollar. We have significant foreign currency exposure through our Australian and Singapore manufacturing activities and our international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures predominantly denominated in euros, Australian dollars and Singapore dollars. Under this program, increases or decreases in our foreign-currency-denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not enter into financial instruments for trading or speculative purposes. The foreign currency derivatives portfolio is recorded in the condensed consolidated balance sheets at fair value and included in other assets or other liabilities. All movements in the fair value of the foreign currency derivatives are recorded within other income, net, on our condensed consolidated statements of income.

The table below provides information (in U.S. dollars) on our foreign currency denominated operating assets and liabilities and after considering our foreign currency hedging activities as of December 31, 2020 (in thousands):

	U.S. Dollar (USD)	Euro (EUR)	Canadian Dollar (CAD)	Chinese Yuan (CNY)
AUD Functional:				
Assets	357,016	106,938	-	23,905
Liability	(280,725)	(120,612)	(5)	(629)
Foreign Currency Hedges	(65,000)	-	-	(24,507)
Net Total	<u>11,291</u>	<u>(13,674)</u>	<u>(5)</u>	<u>(1,231)</u>
USD Functional:				
Assets	-	-	22,050	-
Liability	-	(460)	(1,660)	-
Foreign Currency Hedges	-	-	(15,681)	-
Net Total	<u>-</u>	<u>(460)</u>	<u>4,709</u>	<u>-</u>
SGD Functional:				
Assets	444,105	127,215	-	177
Liability	(159,375)	(52,010)	-	-
Foreign Currency Hedges	(285,000)	(85,597)	-	-
Net Total	<u>(270)</u>	<u>(10,392)</u>	<u>-</u>	<u>177</u>



## RESMED INC. AND SUBSIDIARIES

### Quantitative and Qualitative Disclosures About Market Risk

The table below provides information about our material foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options, collars and forward contracts held at December 31, 2020. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments, including the forward contracts used to hedge our foreign currency denominated assets and liabilities. These notional amounts generally are used to calculate payments to be exchanged under the contracts (in thousands, except exchange rates).

				Fair Value Assets / (Liabilities)	
				December 31, 2020	June 30, 2020
Foreign Exchange Contracts	Year 1	Year 2	Total		
AUD/USD					
Contract amount	65,000	-	65,000	816	
Ave. contractual exchange rate	AUD 1 = USD 0.7615		AUD 1 = USD 0.7615		
AUD/Euro					
Contract amount	48,912	12,228	61,140	1,430	886
Ave. contractual exchange rate	AUD 1 = Euro 0.6239	AUD 1 = Euro 0.6400	AUD 1 = Euro 0.6270		
SGD/Euro					
Contract amount	110,053	-	110,053	347	126
Ave. contractual exchange rate	SGD 1 = Euro 0.6189	-	SGD 1 = Euro 0.6189		
SGD/USD					
Contract amount	285,000	-	285,000	4,603	(183)
Ave. contractual exchange rate	SGD 1 = USD 0.7447		SGD 1 = USD 0.7447		
AUD/CNY					
Contract amount	24,507	-	24,507	539	(161)
Ave. contractual exchange rate	AUD 1 = CNY 4.9450		AUD 1 = CNY 4.9450		
USD/CAD					
Contract amount	15,681	-	15,681	(1,077)	(83)
Ave. contractual exchange rate	USD 1 = CAD 1.3695		USD 1 = CAD 1.3695		

### Interest Rate Risk

We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents and debt. At December 31, 2020, we held cash and cash equivalents of \$255.9 million principally comprised of bank term deposits and at-call accounts and are invested at both short-term fixed interest rates and variable interest rates. At December 31, 2020, there was \$329.0 million outstanding under the Revolving Credit Agreement and Term Credit Agreement, which are subject to variable interest rates. A hypothetical 10% change in interest rates during the three and six months ended December 31, 2020, would not have had a material impact on pretax income. We have no interest rate hedging agreements.

**RESMED INC. AND SUBSIDIARIES****Controls and Procedures**

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports made pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2020.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



**RESMED INC. AND SUBSIDIARIES****Item 1 Legal Proceedings**

We are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. We investigate these matters as they arise, and accrue estimates for resolution of legal and other contingencies in accordance with Accounting Standard Codification Topic 450, “Contingencies”. See note 10 to the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.

**Item 1A Risk Factors**

The discussion of our business and operations should be read together with the risk factors and contained in our annual report on Form 10-K for the fiscal year ended June 30, 2020, which was filed with the SEC and describe various material risks and uncertainties to which we are or may become subject. As of December 31, 2020, there have been no further material changes to such risk factors.

**Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**

**Purchases of equity securities.** On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program.

We temporarily suspended our share repurchase program due to recent acquisitions, and more recently, as a response to the COVID-19 pandemic. As a result, we did not repurchase any shares during the three months ended December 31, 2020. However, there is no expiration date for this program, and we may, at any time, elect to resume the share repurchase program as the circumstances allow. Since the inception of the share buyback programs, we have repurchased 41.8 million shares at a total cost of \$1.6 billion. At December 31, 2020, 12.9 million additional shares can be repurchased under the approved share repurchase program.

**Item 3 Defaults Upon Senior Securities**

None

**Item 4 Mine Safety Disclosures**

None

**Item 5 Other Information**

None

**RESMED INC. AND SUBSIDIARIES****Item 6 Exhibits**

Exhibits (numbered in accordance with Item 601 of Regulation S-K)

- |      |  |
|------|--|
| 3.1  | <a href="#"><u>First Restated Certificate of Incorporation of ResMed Inc., as amended. (Incorporated by reference to Exhibit 3.1 to the Registrant's Report on Form 10-Q for the quarter ended September 30, 2013)</u></a>   |
| 3.2  | <a href="#"><u>Sixth Amended and Restated Bylaws of ResMed Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on February 26, 2020)</u></a>   |
| 31.1 | <a href="#"><u>Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u></a>  |
| 31.2 | <a href="#"><u>Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u></a>  |
| 32   | <a href="#"><u>Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u></a>  |
| 101  | The following financial statements from ResMed Inc.'s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020, filed on January 28, 2021, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Cash Flows, (v) the Notes to the Condensed Consolidated Financial Statements. |

**RESMED INC. AND SUBSIDIARIES**

**Signatures**

We have authorized the persons whose signatures appear below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

January 28, 2021

ResMed Inc.

/s/ **MICHAEL J. FARRELL**

Michael J. Farrell  
Chief executive officer  
(Principal Executive Officer)

/s/ **BRETT A. SANDERCOCK**

Brett A. Sandercock  
Chief financial officer  
(Principal Financial Officer)